ArticleACS omega2026
Surface-Mediated Immunomodulation by Electrostatic Immobilization of Naproxen on Plasma-Aminated Poly(ε-caprolactone) Films Rescues Osteogenic Differentiation via Attenuation of NF-κB Signaling.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammation following biomaterial implantation often leads to fibrous encapsulation and compromised osseointegration, particularly in clinically inflamed environments. We developed a surface-functionalized poly-(ε-caprolactone) (PCL) platform to modulate the early inflammatory microenvironment via surface-mediated drug release. PCL films were aminated by plasma polymerization, enabling the electrostatic immobilization of naproxen. Surface characterization by zeta potential analysis, X-ray photoelectron spectroscopy (XPS), and atomic force microscopy (AFM) confirmed successful amine functionalization and subsequent naproxen loading. The functionalized films exhibited a pronounced early burst release of naproxen within the initial hours after immersion, addressing the early phase of post-surgical inflammation. In vitro studies using MC3T3-E1 pre-osteoblasts under lipopolysaccharide (LPS)-induced inflammatory conditions showed that naproxen released from the surface significantly reduced pro-inflammatory cytokine secretion, including IL-6 and IL-1β. The cytokine-suppressive effect of the naproxen-functionalized surface was further supported by mechanistic experiments showing that soluble naproxen attenuated LPS-induced NF-κB p65 phosphorylation and nuclear translocation. These results suggest that the anti-inflammatory response mediated by surface-released naproxen is, at least in part, attributable to the intrinsic NF-κB-modulating activity of naproxen. Modulation of the inflammatory microenvironment restored osteogenic differentiation, with increased expression of RUNX2, ALP, and OPN, and enhanced matrix mineralization, as confirmed by Alizarin Red S staining. These findings demonstrate that surface-mediated delivery of naproxen enables temporally controlled osteoimmunomodulation and supports osteogenic function under inflammatory stress, underscoring the potential of this surface-engineering strategy for bone-regenerative applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.